Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil

Alessandra Tedeschi • 22 Sep 2019
iwCLL 2019
Lymphoma Chlorambucil Ibrutinib Obinutuzumab
iLLUMINATE

Alessandra Tedeschi, MD, Niguarda Cancer Center, Milan, Italy, discusses the 4-year update of the iLLUMINATE study (NCT02264574) looking at ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Alessandra Tedeschi

1:20
RESONATE-2: Ibrutinib for CLL 5-year follow-up
Alessandra Tedeschi • 21 Sep 2019
17:22
Varying efficacies of combination and monotherapies in CLL
Alessandra Tedeschi et al. • 21 Sep 2019
1:52
RESONATE: five-year follow-up of ibrutinib for CLL
Alessandra Tedeschi • 15 Jun 2019
2:44
Waldenström’s Macroglobulinemia: frontline treatment
Alessandra Tedeschi • 15 Jun 2019

Related Videos

2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
1:51
Investigating resistance mechanisms to bispecific antibodies and CAR-T in patients with lymphoma
Pau Abrisqueta • 5 Apr 2024
The content of VJHemOnc is intended for healthcare professionals